Page 2 - Indian Pharma

DRL to Cipla: Pharma Inc firms up plans to launch anti-obesity drugs

Push comes as patents are set to expire in March 2026

Trump threatens 200% pharma, 50% copper tariffs: What it means for India

As trade tensions escalate under Donald Trump, India finds itself in the crosshairs once again. Donald Trump's proposed duties target two of India's biggest export sectors - pharmaceuticals and copper

Indian pharma eyes US gains as $63.7 bn patent cliff nears: Analysts

Shift is expected to drive a sharp increase in generic drug launches, positioning Indian drugmakers for strong growth

Indian pharma market grows 7.2% in May led by chronic therapies

Indian pharma market grew 7.2% in May with strong performance in chronic therapies such as cardiac and anti-infectives, along with gains from price hikes and new launches

Trade talks: India to push US to lift non-tariff curbs for goods exporters

The official said industry has raised regulatory hurdles and high cost of certification among other issues in the US as primary obstacles to increasing exports to the US

Trump's plans to cut drug prices in US may impact Indian pharma landscape

Trump's executive order, dated May 12, seeks to establish a mechanism through which American patients can buy their drugs directly from the manufacturers

Medical device company share price zooms 47% in 1 month. Do you own?

Poly Medicure, a leading medical device company with a dominant position in India's medical consumables market, rallied 5 per cent to ₹2,922 on the BSE in Wednesday's intra-day trade.

Short-term painkiller? Pharma Inc gets a breather from US tariffs

Tariff worries, raw material costs still ail sector

Indian pharma market registers 7.5% growth in Feb 2025: Pharmarack

Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, and 6 per cent, respectively

India pharma exports surge 9%, outpacing global average, says report

India has also surpassed the US in the number of FDA-registered generic manufacturing sites

India's pharma exports set for 10x growth, targeting $350 billion by 2047

Indian biosimilar exports, presently valued at $0.8 billion, are expected to grow fivefold to $4.2 billion by 2030 and reach $30-35 billion by 2047

AI, machine learning to help Indian pharma industry to pivot on innovation

As technological advancements like AI, machine learning and precision medicine revolutionise drug discovery, manufacturing and patient care, Indian pharmaceutical industry is set for a 'profound transformation' in 2025 with innovation, wider global access and improvement in quality becoming key themes for the future. The industry, which is expected to grow nearly two-fold to around USD 130 billion in size by 2030, is looking to take advantage of conducive policies, demographic and digital talent, in making India play a pivotal role in advancing global health for all. Currently accounting for around 20 per cent of the overall generic drug sales globally, the Indian pharma industry is focussing on research excellence and innovation in order to position the country as a global hub for high-quality, affordable pharmaceuticals. "The Indian pharma market is expected to move up to USD 120-130 billion by 2030 from the current size of USD 58 billion. Initiatives in terms of quality, innovati

India to add 50 new pharma greenfield plants under PLI scheme: Pharma Secy

He stated that the Indian meditech industry also exported more than the country imported in the surgical and consumable space

World Pharmacist Day 2024: Date, History, significance, wishes and quotes

Every year on September 25, 2023, World Pharmacist Day is observed as a special day to honour and acknowledge pharmacists for their enormous contributions to enhancing world health

Indian pharma firms seek govt tax reliefs, incentives to spur innovation

The upcoming budget would be Modi's first major policy announcement in his third term as prime minister

Indian pharma cos make versions of Wegovy to get in on weight-loss windfall

Novo has not provided a clear timeline for introducing Wegovy globally, but told Reuters it aims to launch in India in 2026

Indian drug firms look for new opportunities in Saudi Arabia pharma market

Indian drug firms sense opportunity to increase presence in $8.9 bn Saudi market

Trade generics growth to dent value expansion of domestic drug market

Jan Aushadhi and trade generics together constitute 20-22% of pharma market volumes

USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant

The US health regulator has pulled up Intas Pharmaceuticals for manufacturing lapses, including violation of current good manufacturing practice (CGMP) regulation, at its Ahmedabad-based plant. In a warning letter to the company's CEO and MD Nimish Chudgar, the US Food and Drug Administration (USFDA) has pointed out various manufacturing lapses at the Matoda-Sanand, Ahmedabad-based facility. A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations. The USFDA inspected the facility from May 1-12, 2023. "This warning letter summarises significant violations of CGMP regulations for finished pharmaceuticals... Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated," it noted. In the warning letter, the health regulator pointed out the company "failed to exercise its responsibility to ensure drug products manufactured

Indian pharma industry can grow to $450 bn by 2047: EY-OPPI report

The report underlines the need for collaboration and alignment between the industry, academia and government to advance research and innovation capabilities